GlassScriptPhysician profile
Thaleshravi Prashad
NPI 1427691302
$6,359.75
in general payments reported to CMS, 2019-2025
33 companies · $824 in 2025
The $824 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,015 · 2022: $2,651 · 2023: $1,384 · 2024: $486 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $900 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.64 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $900.00 |
| Education | $268.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $936.90 | 2022-2023 | |
| Epizyme, INC. | $720.26 | 2022 | |
| Janssen Biotech, INC. | $614.26 | 2021-2025 | Darzalex, Tecvayli |
| Ipsen Biopharmaceuticals, INC | $540.00 | 2022 | |
| Incyte Corporation | $435.24 | 2021-2023 | Pemazyre |
| Astrazeneca Pharmaceuticals LP | $382.70 | 2022-2024 | |
| Genzyme Corporation | $267.34 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $259.94 | 2025 | Ultomiris, Soliris |
| Beigene USA, INC. | $216.64 | 2021-2024 | Brukinsa |
| Beone Medicines USA, INC. | $180.43 | 2025 | Brukinsa |
| Sobi, INC | $170.76 | 2023-2024 | |
| Glaxosmithkline, LLC. | $169.10 | 2022-2024 | Ojjaara |
| Coherus Oncology, INC. | $150.00 | 2021 | |
| Amgen INC. | $133.56 | 2021 | |
| Daiichi Sankyo INC. | $125.00 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $122.19 | 2024 | Ogsiveo |
| Genmab U.S., INC. | $115.65 | 2023-2025 | Epkinly |
| Gilead Sciences, INC. | $104.87 | 2022 | |
| Lilly USA, LLC | $102.29 | 2023-2024 | Verzenio, Jaypirca |
| Celgene Corporation | $100.51 | 2022-2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $99.99 | 2022 | |
| Sanofi-Aventis U.S. LLC | $83.00 | 2022 | |
| Taiho Oncology, INC. | $51.91 | 2025 | |
| Adaptive Biotechnologies Corporation | $45.09 | 2025 | Clonoseq |
| Geron Corporation | $44.72 | 2025 | Rytelo |
| Karyopharm Therapeutics INC. | $34.60 | 2025 | Xpovio |
| Astellas Pharma US INC | $31.34 | 2025 | Cresemba |
| Abbvie INC. | $25.16 | 2025 | |
| Novartis Pharmaceuticals Corporation | $24.12 | 2022 | |
| Genentech USA, INC. | $20.22 | 2023 | |
| Seagen INC. | $18.20 | 2023 | Adcetris |
| Bayer Healthcare Pharmaceuticals INC. | $18.01 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $15.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaleshravi Prashad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.